Digital biomarkers for Alzheimer's Disease with compact dual-mode brain sensing

具有紧凑型双模式脑传感功能的阿尔茨海默病数字生物标记

基本信息

批准号：
10526163
负责人：
HANLI LIU
金额：
$ 38.85万
依托单位：
UNIVERSITY OF TEXAS ARLINGTON
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-15 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10526163
关键词：
Age Algorithms Alzheimer disease detection Alzheimer&apos s Disease Alzheimer&apos s disease brain Alzheimer&apos s disease caregiver Alzheimer&apos s disease diagnosis Alzheimer&apos s disease patient Alzheimer’s disease biomarker Anatomy Applications Grants Autopsy Base of the Brain Biological Biological Markers Biomedical Engineering Brain Cerebrum Data Science Dementia Detection Deterioration Development Devices Early Diagnosis Elderly Electroencephalogram Electrophysiology (science)Forehead Frequencies Head Human Human Activities Impairment Mathematics Measurement Measures Metabolic Metabolic dysfunction Metabolism Methods National Institute on Aging Near-Infrared Spectroscopy Outcome Pathologic Pathologic Processes Patients Persons Population Research Research Project Grants Rest Severities Signal Transduction Social Work Societies Stratification Symptoms System Task Performances Testing base cerebral blood volume classification algorithm computerized data processing cost cost effective dementia care digital early detection biomarkers effective intervention experience hemodynamics high risk human subject in vivo machine learning classification mathematical sciences multidisciplinary neurophysiology neurovascular coupling novel older patient recruit sensor technology success wireless

项目摘要

Digital biomarkers for Alzheimer's Disease with compact dual-mode brain sensing In 2018, the National Institute on Aging and Alzheimer's Association jointly created a “research framework,” providing a new biological definition of Alzheimer's disease (AD) by emphasizing a biological construct and focuses on the diagnosis of AD with biomarkers in living persons [1]. Now, “Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers.” [1] It is highly desirable to develop and validate digital biomarkers for early detection of AD. It is even better if such digital biomarkers can be measured with compact devices. It is known that the AD brain has significant degenerations in all anatomical, biological, and pathological aspects. Such deteriorations must be accompanied by cerebral dysfunctions of metabolic, hemodynamic, and electrophysiological (MHE) activities in the AD brain. Also, the progression from early to late stage of AD takes years and often shows no or few symptoms at the early stage. However, cutting-edge, biological-construct- based, brain-sensing technology may enable to detect progressive degeneration of MHE-activity. The hypothesis of this study is that patients with AD are impaired in their cerebral MHE functions and can be sensed by digital biomarkers derived from 15-min, resting-state brain measurements concurrently taken with compact, dual-mode, broadband near infrared spectroscopy (bbNIRS) and dry/wireless electroencephalogram (dwlEEG) from potential patients with AD. Specifically, we wish to conduct a proof-of-principle study, namely, to develop, test, and demonstrate a novel AD-sensing system by integrating bbNIRS and dwlEEG (bbNIRS+dwlEEG) as a compact, dual-mode, low-cost, and high-efficient device. The proposed bbNIRS+dwlEEG device enables us to perform resting-state human brain measurements which will result in quantifications of (1) cerebral metabolism, (2) cerebral blood volume and oxygenation, and (3) brain rhythm powers and connectivity oscillating at different frequencies, respectively, from both normal subjects and patients with AD. For this R21 proposal, specifically, we have two aims: Aim 1 is to establish digital biomarkers or features of cerebral MHE-activities of the healthy human brain based on resting- state, neurophysiological measures with a compact bbNIRS+dwlEEG system. Aim 2 is to identify appropriate biomarkers that can accurately separate healthy older adults from patients with AD as well as to stratify AD patients based on the stages of dementia (mild and moderate-to-severe). The outcome of this R21 will provide proof of principle that the dual-mode bbNIRS+dwlEEG system enables to identify critical digital biomarkers that will enable accurate detection and stratification of AD at mild or moderate-to-severe stage, permitting us to pursue a larger research project (i.e., R01) for promoting digital biomarkers for early detection of AD by a compact, low-cost, effective, dual-mode brain sensing system.

具有紧凑型双模式脑传感功能的阿尔茨海默病数字生物标记 2018年，美国国家老龄化研究所和阿尔茨海默病协会联合创建了一个“研究框架”，通过强调生物学结构和提供阿尔茨海默病（AD）的新生物学定义专注于利用活人生物标志物诊断 AD [1] 现在，“阿尔茨海默病 (AD) 已被定义。通过其潜在的病理过程，可以通过尸检或体内记录来记录 [1] 非常需要开发和验证用于早期检测 AD 的数字生物标记。如果可以使用紧凑型设备测量此类数字生物标记，那就更好了。众所周知，AD 大脑在所有解剖学、生物学和病理学方面都有显着的退化。这种恶化必定伴随着脑代谢、血流动力学和功能障碍。 AD 大脑中的电生理 (MHE) 活动此外，AD 从早期到晚期的进展也需要时间。数年，并且在早期阶段通常没有或很少表现出症状，但是，尖端的生物结构 - 基于大脑传感技术可以检测 MHE 活动的进行性退化。这项研究的假设是，AD 患者的大脑 MHE 功能受损，并且可以通过 15 分钟静息状态大脑测量同时进行的生物标记数字来感知紧凑型、双模式、宽带近红外光谱 (bbNIRS) 和干/无线脑电图 (dwlEEG) 来自潜在的 AD 患者。具体来说，我们希望进行原理验证研究，即开发、测试和演示一种新颖的 AD 传感系统通过集成 bbNIRS 和 dwlEEG (bbNIRS+dwlEEG) 作为紧凑型、双模式、低成本、所提出的 bbNIRS+dwlEEG 设备使我们能够进行静息态人体实验。大脑测量，这将导致（1）脑代谢，（2）脑血容量的量化和氧合，以及（3）分别以不同频率振荡的脑节律功率和连接性，对于这个 R21 提案，我们有两个目标：目标 1 是基于静息状态建立健康人脑的脑 MHE 活动的数字生物标志物或特征状态，使用紧凑的 bbNIRS+dwlEEG 系统进行神经生理学测量，目标 2 是确定合适的。生物标志物可以准确区分健康老年人和 AD 患者并对 AD 进行分层根据痴呆症的阶段（轻度和中度至重度）的患者。 R21 的成果将为双模式 bbNIRS+dwlEEG 系统提供原理证明能够识别关键的生物标志物数字，从而实现 AD 的准确检测和分层在轻度或中度至重度阶段，使我们能够开展更大的研究项目（即 R01）推广数字生物标志物，通过紧凑、低成本、有效的双模式大脑来早期检测 AD 传感系统。